Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.55 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.52 |
| ▸ | MAPT | P10636 | 1/20 | 0.51 |
| ▸ | RECQL | P46063 | 1/20 | 0.49 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.46 |
| ▸ | CTSS | P25774 | 1/20 | 0.46 |
| ▸ | CTSK | P43235 | 1/20 | 0.46 |
| ▸ | TSHR | P16473 | 1/20 | 0.46 |
| ▸ | PPARA | Q07869 | 5/20 | 0.44 |
| ▸ | PPARG | P37231 | 4/20 | 0.44 |
| ▸ | ACE | P12821 | 1/20 | 0.43 |
| ▸ | GAA | P10253 | 1/20 | 0.43 |
| ▸ | PPARD | Q03181 | 2/20 | 0.43 |
| ▸ | NPC1 | O15118 | 1/20 | 0.42 |
| ▸ | RAB9A | P51151 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4937239 | 1.00 | HDAC6 (0.55) | HDAC6ALDH1A1MAPTRECQLPTPN1 | |
| SCHEMBL30559535 | 0.90 | MAPT (0.54) | HDAC6ALDH1A1MAPTRECQLPTPN1 | |
| SCHEMBL26976591 | 0.90 | MAPT (0.54) | HDAC6ALDH1A1MAPTRECQLPTPN1 | |
| SCHEMBL27126432 | 0.90 | MAPT (0.54) | HDAC6ALDH1A1MAPTRECQLPTPN1 | |
| SCHEMBL4933982 | 0.88 | HDAC6 (0.49) | HDAC6ALDH1A1MAPTRECQLCTSS | |
| SCHEMBL4933962 | 0.88 | HDAC6 (0.49) | HDAC6ALDH1A1MAPTRECQLCTSS | |
| SCHEMBL24754664 | 0.86 | BRD4 (0.41) | HDAC6ALDH1A1RECQLPTPN1CTSS | |
| SCHEMBL29184736 | 0.86 | BRD4 (0.41) | HDAC6ALDH1A1RECQLPTPN1CTSS | |
| SCHEMBL29184721 | 0.86 | BRD4 (0.41) | HDAC6ALDH1A1RECQLPTPN1CTSS | |
| SCHEMBL4927920 | 0.86 | HDAC6 (0.47) | HDAC6ALDH1A1MAPTRECQLCTSS |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080132539-A1 | Hydroxamic Acid Derivative And Age Generation Inhibitor Containing The Derivative | KUREHA CORPORATION (JP) | 2008-06-05 | — | — | US | disclosed |
| EP-1707560-A1 | HYDROXAMIC ACID DERIVATIVE AND AGE GENERATION INHIBITOR CONTAINING THE DERIVATIVE | Kureha Corporation (JP) | 2006-10-04 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080132539-A1 | Hydroxamic Acid Derivative And Age Generation Inhibitor Containing The Derivative | HDAC5, HDAC1, HDAC9 | HDAC6 10/4885ALDH1A1 1829/4885MAPT 2275/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.